Camrelizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | PD1 |
Clinical data | |
Synonyms | SHR-1210 |
ATC code |
|
Identifiers | |
CAS Number |
Camrelizumab (SHR-1210) (INN[1]) is a monoclonal antibody that is being investigated for hepatocellular carcinoma.
This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2018, camrelizumab is undergoing Phase II/III trials.
References
- ↑ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.